627 related articles for article (PubMed ID: 19368810)
1. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
Yin GN; Lee HW; Cho JY; Suk K
Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease.
de la Monte SM; Volicer L; Hauser SL; Wands JR
Ann Neurol; 1992 Dec; 32(6):733-42. PubMed ID: 1471863
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
[TBL] [Abstract][Full Text] [Related]
4. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
5. Proteome studies of CSF in AD patients.
Davidsson P; Sjögren M
Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.
Finehout EJ; Franck Z; Choe LH; Relkin N; Lee KH
Ann Neurol; 2007 Feb; 61(2):120-9. PubMed ID: 17167789
[TBL] [Abstract][Full Text] [Related]
7. Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease.
Sáez-Valero J; Costell M; Sjögren M; Andreasen N; Blennow K; Luque JM
J Neurosci Res; 2003 Apr; 72(1):132-6. PubMed ID: 12645087
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
10. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions.
Yin GN; Jeon H; Lee S; Lee HW; Cho JY; Suk K
J Neurosci Res; 2009 Aug; 87(11):2578-90. PubMed ID: 19360901
[TBL] [Abstract][Full Text] [Related]
11. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease.
Kaiser E; Schoenknecht P; Kassner S; Hildebrandt W; Kinscherf R; Schroeder J
Neurodegener Dis; 2010; 7(4):251-9. PubMed ID: 20551690
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression.
Behan AT; Byrne C; Dunn MJ; Cagney G; Cotter DR
Mol Psychiatry; 2009 Jun; 14(6):601-13. PubMed ID: 18268500
[TBL] [Abstract][Full Text] [Related]
14. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
Isobe C; Murata T; Sato C; Terayama Y
Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
[TBL] [Abstract][Full Text] [Related]
15. Identification of oxidized plasma proteins in Alzheimer's disease.
Choi J; Malakowsky CA; Talent JM; Conrad CC; Gracy RW
Biochem Biophys Res Commun; 2002 May; 293(5):1566-70. PubMed ID: 12054695
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes.
Strekalova H; Buhmann C; Kleene R; Eggers C; Saffell J; Hemperly J; Weiller C; Müller-Thomsen T; Schachner M
Neurobiol Aging; 2006 Jan; 27(1):1-9. PubMed ID: 16298234
[TBL] [Abstract][Full Text] [Related]
17. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.
Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K
Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155
[TBL] [Abstract][Full Text] [Related]
18. Expression of the neural cell adhesion molecule (NCAM) in Alzheimer's disease.
Gillian AM; Brion JP; Breen KC
Neurodegeneration; 1994 Dec; 3(4):283-91. PubMed ID: 7842299
[TBL] [Abstract][Full Text] [Related]
19. Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry.
Hesse C; Nilsson CL; Blennow K; Davidsson P
Electrophoresis; 2001 May; 22(9):1834-7. PubMed ID: 11425239
[TBL] [Abstract][Full Text] [Related]
20. CSF cortisol in Alzheimer's disease and mild cognitive impairment.
Popp J; Schaper K; Kölsch H; Cvetanovska G; Rommel F; Klingmüller D; Dodel R; Wüllner U; Jessen F
Neurobiol Aging; 2009 Mar; 30(3):498-500. PubMed ID: 17716786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
